4SC AG (Frankfurt, Prime Standard: VSC/ISIN DE0005753818) discovers and develops small-molecules for autoimmune and cancer indications. 4SC-101, a novel autoimmune modulator, is in a Phase IIb study in rheumatoid arthritis as well as a Phase IIa exploratory study in inflammatory bowel disease. The company’s lead oncology compound, resminostat (4SC-201), a pan-histone-deacetylase inhibitor, is in two Phase II trials in hepatocellular carcinoma and Hodgkin’s Lymphoma. Two further oncology compounds 4SC-203 and 4SC-205 are due to commence Phase I trials. Drug candidates are developed until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

4SC was founded in 1997, has 93 employees and is based in Martinsried/Munich, Germany. The company has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

For further information please visit http://www.4sc.com

Login or register to write a review